The Week That Was, The Week Ahead: Macro and Markets, October 25
U.S. stocks finished Friday lower as rising oil prices and renewed inflation concerns weighed on Wall Street. The Dow Jones Industrial Average (DJI...
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lee Munder Capital Group Lee Munder | 37,703 | $28,589,085 | +3% | 1.54% |
| 2. | Polaris Capital Management Bernard Horn | 25,040 | $18,987,081 | 1.99% | |
| 3. | Motley Fool Asset Management Bryan Hinmon | 7,012 | $5,316,989 | 0.2% | |
| 4. | Bailard Inc Thomas Bailard | 3,376 | $2,560,473 | 0.05% | |
| 5. | Ranmore Fund Management Sean Peche | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $781.47 | 50 | $39,073.50 | 47,833 | 2026-10-14 | Filing | |
| $780.63 | 463 | $361,431.69 | 47,883 | 2026-10-14 | Filing | |
| $779.59 | 380 | $296,244.20 | 48,346 | 2026-10-14 | Filing | |
| $778.64 | 454 | $353,502.56 | 48,726 | 2026-10-14 | Filing | |
| $777.76 | 38 | $29,554.88 | 49,180 | 2026-10-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 402,958 | $305,550,967 | 0.37% | |
| 2. | 278,120 | $210,890,052 | 0.12% | |
| 3. | 188,572 | $142,988,492 | 0.12% | |
| 4. | 172,649 | $130,914,557 | 10.75% | |
| 5. | 126,572 | $95,975,750 | 0.17% |
News See All
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals' (REGN) Solid Financial Results
Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here.
Claude AI Portfolio: 8 Best-Performing Stocks in 2026
The use of AI for stock picking among retail and institutional investors is rising.
10 Stocks With Low Debt and Strong Free Cash Flow
Low debt and strong free cash flow give a company room to keep investing when demand weakens, financing becomes less attractive or competitors need to conserve cash.
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage.
Here's Why The Fund Sold Regeneron Pharmaceuticals (REGN)
American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”.
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here.
Can Regeneron (REGN)'s Rare-Disease Win Move the Earnings Needle?
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva.
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here.
Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims
A class action lawsuit was filed against biotechnology company Regeneron ($REGN) on July 16, which could put further pressure on its troubled share...
Hedge Fund Resource Center